Walvax Biotechnology Co., Ltd. (SHE: 300142)

Market Cap	16.07B
Revenue (ttm)	3.38B
Net Income (ttm)	134.71M
Shares Out	1.60B
EPS (ttm)	0.08
PE Ratio	119.35
Forward PE	31.41
Dividend	0.01 (0.10%)
Ex-Dividend Date	May 30, 2024

Volume	14,397,868
Open	10.26
Previous Close	10.14
Day's Range	9.98 - 10.26
52-Week Range	9.98 - 25.45
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2023, Walvax Biotechnology's revenue was 4.11 billion, a decrease of -19.12% compared to the previous year's 5.09 billion. Earnings were 419.39 million, a decrease of -42.44%.